
    very slow accrual; terminated to allow resources to be utilized more effectively on other
    studies. no data analysis completed, nor any conclusions reached.
  
['non-hodgkin lymphoma', 'hodgkin lymphoma', 'kaposi sarcoma', 'gastric cancer', 'nasopharyngeal cancer', 'ebv', 'castleman disease']
['nelfinavir']

        Inclusion Criteria:

          -  Age 18 years or older

          -  Biopsy proven EBV(+) or KSHV(+) malignancy

          -  Relapsed/refractory disease failing > 2 prior therapies

          -  Measurable, non-bony disease (at least one lesion on radiographic or physical exam
             assessment measuring > 2 cm in longest axis)

          -  KS patients with skin-only disease must have cutaneous lesions amenable to four 3 mm
             punch biopsies during the course of the study

          -  Eastern Cooperative Oncology Group (ECOG) performance status < 2

          -  Life expectancy of greater than 12 weeks

          -  Patients must be able to lie flat for at least 60 minutes and fit on a PET-CT scanner

          -  Ability to comply with an oral drug regimen

          -  Females of childbearing potential must have a negative pregnancy test at screening

          -  Patients must have normal organ and marrow function as defined below within 14 days of
             study entry

        Exclusion Criteria:

          -  Patients with HIV-associated primary central nervous system lymphoma

          -  Radiotherapy or chemotherapy ending within 14 days of study enrollment

          -  Patients currently on other protease inhibitors

          -  Chronic diarrhea

          -  Acute, active infection within 14 days of enrollment

          -  Patients on active treatment for hypo- or hyperthyroidism

          -  End-stage liver disease unrelated to tumor

          -  Hepatitis B or hepatitis C infection

          -  Use of any other type of investigational agent or treatment concurrently or within 28
             days before the first dose of study treatment

          -  History of iodine hypersensitivity

          -  Females who are pregnant or breastfeeding

          -  Physical or psychiatric conditions that in the estimation of the investigator place
             the patient at high risk of toxicity, non-compliance, or inability to complete the
             study requirements

          -  Use of drugs to treat or prevent herpesvirus infections

          -  Essential medication that is known to interact with nelfinavir
      